---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-047882"
form_type: "8-K"
ticker: "PHAT"
cik: "0001783183"
company_name: "Phathom Pharmaceuticals, Inc."
filed_at: "2025-03-06T23:59:59+00:00"
generated_at: "2026-05-25T07:03:11.157566+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Phathom Pharma Q4 revenue $29.7M; VOQUEZNA prescriptions up 81% QoQ

## Summary
- FY2024 net revenue $55.3M from VOQUEZNA launch; Q4 revenue $29.7M (81% increase vs Q3).
- Over 300,000 filled prescriptions launch-to-date, up ~110% since last earnings report.
- Q4 net loss $74.5M; non-GAAP adjusted net loss $56.4M vs $46.0M in prior year Q4.
- SG&A expenses rose to $290.7M in FY2024 vs $117.9M in FY2023 due to commercial buildout.
- Phase 2 EoE trial for VOQUEZNA to begin enrollment in Q2 2025.

## SEC filing metadata
- accession: 0001193125-25-047882
- form_type: 8-K
- ticker: PHAT
- cik: 0001783183
- company_name: Phathom Pharmaceuticals, Inc.
- filed_at: 2025-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783183/000119312525047882/0001193125-25-047882-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783183/000119312525047882/d940367d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-047882
- JSON: https://secwatch.observer/filing/0001193125-25-047882.json
- Plain text: https://secwatch.observer/filing/0001193125-25-047882.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.